The adenosine-induced immunosuppression hampers the immune response toward tumor cells and facilitates the tumor cells to evade immunosurveillance. CD73, an ecto-5-nucleotidase, is the ectoenzyme dephosphorylating extracellular AMP to adenosine. Here, using immunocompetent transgenic head and neck squamous cell carcinoma (HNSCC) mouse model, immune profiling showed high expression of CD73 on CD4
Head and neck squamous cell carcinoma (HNSCC) is a highly immunosuppressive disease. 1 The immunosuppression, which is induced by the exhaustion of effector cells, production of immunosuppressive mediators and recruitment of immunosuppressive cells, facilitates HNSCC cells to escape from immunosurveillance and prevents tumor elimination via multiple mechanisms. [2] [3] [4] The immunosuppressive status of HNSCC raises the possibility that immunotherapy could be an effective approach to HNSCC treatment. 5 Recently, the immunotherapy has revolutionized the treatment of cancers. Therapeutics that target inhibitory immune checkpoints, such as programmed cell death protein 1(PD-1), have generated durable and effective antitumor responses in cancer patients, including HNSCC. 6 However, some patients are nonresponsive to this kind of immunotherapy, indicating that alternative immunosuppressive mechanisms must be studied. 7 Thus, a better understanding of the various aspects of tumorinduced immunosuppression would benefit the exploration and development of novel immunotherapeutic strategies. Adenosine is one of the immunosuppressive mediators involved in tumor progression. 8, 9 Adenosine plays a crucial role in the hypoxia-driven immunosuppression and, thereby hampers the immune response towards tumor cells in various cancer. 10 CD73, a GPI-anchored enzyme, is a crucial enzyme in conversion of immune-activating ATP into immunosuppressive adenosine. 11, 12 Current studies demonstrate that cancers, including HNSCC cells, and the expression of CD73 confers poor prognosis. 13, 14 Notably, CD73 on regulatory T cells (Tregs) impairs antitumor T cell responses. 15, 16 Therapeutics that target CD73 alleviates suppression of the adaptive immune system, thereby enhancing antitumor responses. 17, 18 Nevertheless, whether CD73 blockade reverses the immunosuppression and constitutes an effective therapeutic target in HNSCC remains to be shown.
Inhibitory checkpoints contribute to exhaustion of T cells and serve as the markers for dysfunctional lymphocytes. 19 Recent studies indicated anti-CD73 treatment may synergize with inhibitory checkpoint blockade in cancer immunotherapy. 20 However, the underlying mechanism is not investigated. A recent report pointed out CD73 expression on CD8 1 T cells is inversely associated with cell activation in HIV patients. 21 Therefore, detailed studies on the relationship between CD73 and inhibitory checkpoint on CD8 1 T cells will be beneficial to the understanding of the immunosuppression in HNSCC.
In this study, we utilized immunocompetent transgenic mice model to determine the expression of CD73 on immune cells. We also carried out in vivo studies to investigate the immunomodulatory effects on T cells and therapeutic potentials of the blockade of CD73 with monoclonal antibody (mAb). At last, the human tissue microarrays were used to analyze the expression of CD73 and its relationship with clinic-pathological parameters.
Materials and Methods

Mice
The Tgfbr1/Pten 2cKO mice was described as previously. 22, 23 In briefly, the mice (Tgfbr1 Deletion of Tgfbr1 and Pten in head and neck epithelia induces tumor lesion, after tamoxifen was applied in the oral cavity for 5 consecutive days. The mice were genotyped as previously reported. 22 The mice were housed and maintained under SPF conditions in the School and Hospital of Stomatology at Wuhan University. All animal experiments were approved and supervised by the Institutional Animal Care and Use Committee of Wuhan University. Mice were handled under the NIH guidelines for the Care and Use of Laboratory Animals.
In vivo CD73 antibody treatment
The Tgfbr1/Pten 2cKO mice were randomized into two groups (6 in each group) after tamoxifen induction. Then, the mice received treatment with isotype control (control group, rat IgG2a, Clone:2A3, 100 lg/mouse; BioXcell) or anti-CD73 mAb (aCD73 group, In Vivo CD73 monoclonal antibody, Clone:TY/23, BioXcell) by intraperitoneally injection (twice per week). Throughout the study, the tumor size was measured with a caliper every 5 day. The photos were taken at Day 7 and Day 25. The treatment was stopped at 4 weeks after the initial treatment. Two days later, the mice were euthanized and the tissues were harvested for the flow cytometry analysis.
Flow cytometry
Single-cell suspensions from spleen, draining lymph nodes and peripheral blood were prepared as previously described. 24 After nonspecific Fc-receptor blocking, the cells were stained with the antibodies against: CD4 (RM4-5), CD8 (53-6.7), CD73 (TY/11.8), PD-1 (J43), IFN-g (XMG1.2) (eBioscience) and CTLA-4 (UC10-4B9, BioLegend). 
Immunohistochemistry
The immunohistochemistry protocol was described as previously. 25 In brief, the slides were deparaffinized and 
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rehydrated. The antigens were retrieved by boiling in sodium citrate. Sections were blocked with goat serum, then stained with CD73 (Cell Signaling Technology). The procedure was done with the DAB kit (Mxb Bio). Negative control was set in parallel.
Scoring system
Pannoramic MIDI (3DHISTECH Ltd.) scanner was exploited for scanning all slices and quantifying the histoscore of each sample with background subtraction as previously described. 22 Immunohistochemical staining of the membrane, nuclei and cytoplasm in the interested region was quantified respectively by the Quant Center module of Pannoramic Viewer software (3DHISTECH Ltd.). Histoscore was calculated as previously described. 22 Briefly, scanned high power field of each sample, membranous and nuclear immunostaining was quantified using the algorithm: (1 3 the percentage of weakly positive staining) 1 (2 3 the percentage of moderately positive staining) 1 (3 3 the percentage of strongly positive staining). 26, 27 Quantification of cytoplasmic intensity was calculated as total intensity/total cell number. The threshold for scanning of different positive cells was set by a pathologist. To evaluate the expression of CD73 on tumor infiltrating lymphocytes, the histoscore of CD73 was determined by the calculated method of membranous staining.
Data bases
We downloaded mRNA expression data of head and neck squamous carcinomas (HNSC) from the Cancer Genome Atlas (TCGA). 28 The data on TCGA were stored in four levels and we adopted level 3. The HNSC dataset contains mRNA expression levels of 520 samples from tumor patients and 44 from normal controls. R package TCGAbiolinks was used to download and parse data from TCGA database and to create expression matrices as previously described. 29 TCGAbiolinks was also used to perform univariate KaplanMeier survival analysis on the downloaded data.
Gene set enrichment analysis
Gene set enrichment analysis was performed on the GSEA software (Broad Institute, Massachusetts Institute of Technology) as described in the previous article. 30 Gene sets were downloaded from Molecular Signatures Database (MSigDB; Broad Institute, Massachusetts Institute of Technology). All gene sets that met the false discovery rate (FDR) q-value 0.25 were considered significant as indicated in the previous article. 30 
Statistical analysis
The statistical significance of the differences was determined by Student's t test for comparison between groups and Oneway ANOVO followed Tukey test for three groups. GraphPad Prism 6.0 (Graph Pad Software Inc) was used for the statistical analysis mentioned above. For univariate analysis of overall survival, Kaplan-Meier estimate and the log-rank test was used with GraphPad Prism 6.0. And for multivariate analyses of overall survival, Cox proportional hazards regression model was used with SPSS 22.0 (IBM). The data was displayed as mean 6 SEM. For all tests, statistical differences were considered significant if p < 0.05.
Results
CD73 is upregulated on CD4
1 and CD8 1 T cells and associated with "exhausted" phenotype in tumor-bearing mice
The immunocompetent mouse model is a powerful tool for cancer immunology. According to a previous report, a Tgfbr1/Pten double conditional knockout (2cKO) HNSCC mouse model was generated (Fig. 1a ). In this model, Pten knockout results in the activation of PI3K/Akt pathway, and the Tgfbr1 deletion in the epithelia of head and neck enhanced paracrine effect of TGF-b and the recruitment of immunosuppressive cells in the tumor stroma. 23 This model was selected to study tumor immunity owing not only to the similarity of pathology with human HNSCC but also to the immunocompetence of the mouse model. 23, 24 First, we utilized immunohistochemistry to test the expression of CD73, the result showed the CD73 expression was upregulated in tumor bearing mice compared with normal oral mucosa (Fig.  1b) . Further, by comparing the expression of CD73 between wild-type mice and 2cKO tumor bearing mice, we observed significantly increased CD73 expression on CD4 Fig. 4b and Supporting Information, Fig. 1b) . To further test whether anti-CD73 mAb treatment restored cytokine production, we examined the production of IFN-g in CD4 1 /CD8 1 T cells after PMA stimulation in vitro. There is a significantly increased IFN-g production in CD4
1 /CD8 1 T cells after anti-CD73 mAb treatment (Fig. 4c) . Remarkably, the expression of CTLA-4 and PD-1 in CD73 mAb treatment group exhibited a significantly decrease on CD4 1 and CD8 1 T cells as compared with isotype control group except that CD4 1 T cells did not express significantly less PD-1 in peripheral blood group (Fig. 4d Supporting Information, Fig. 1c ). We also demonstrated that CD73 is highly expressed on CD4 
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Deng et al. Fig. 2b ). In addition, we also measured the expression of CD73 and CTLA-4 on Tregs. Indeed, we observed that both CD73 and CTLA-4 expression were significantly downregulated after anti-CD73 mAb treatment (Supporting Information, Fig. 2c) . All these data demonstrate that the blockade of CD73 in HNSCC in part alleviates suppression of T cells. 
Anti
CD73 is upregulated on the tumor infiltrating immune cells in primary human HNSCC
Owing to the antitumor effect of CD73 blockade in HNSCC mouse model, we want to preliminarily explore the expression of CD73 in human HNSCC samples. To determine whether CD73 expression is associated with human HNSCC, we took advantage of publicly available datasets through Oncomine.
31 NT5E (encoding CD73) mRNA or DNA copy number were found to be significantly increased in 8 out of 17 datasets at a certain cut-off (p < 0.05, fold change > 1.5, Supporting Information, Fig. 3a) . The mRNA level of NT5E was significantly higher in HNSCC samples as compared with oral mucosa (All p < 0.05, Supporting Information, Figs. 3b and 3c). Since elevated CD73 gene expression has been observed, we wished to investigate the protein expression of CD73 in human HNSCC specimen. Immunohistochemical study for CD73 were performed, and automatic membrane staining quantification software was used to assess CD73 expression in the tumor infiltrating immune cells of human HNSCC. As indicated in Figures 6a and 6b , the results showed expression level of CD73 was significantly higher in HNSCC (n 5 134) as compared with normal mucosa (n 5 22, p < 0.05). Then, we assessed the relationships between CD73 expression and various clinicopathological features. However, there were no significant differences in CD73 histoscores in different pathological grades, tumor sizes and lymph node status (Fig. 6c) . In addition, no significant correlation was observed between the expression of CD73 and gender, age, cigarette smoking or alcohol consumption in primary HNSCC ( Supporting Information, Fig. 4 ). Our data thus suggest that primary human HNSCC exhibited elevated CD73 expression.
CD73 is correlated with poor prognosis and negative regulation of immunity A total of 69.4% (93/134) of HNSCC specimens were positive for CD73 in the tumor infiltrating immune cells. To investigate whether the positive expression of CD73 in the tumor infiltrating immune cells influenced overall survival rate, we divided the specimens into two groups (CD73 1 group and CD73 2 group) and evaluated the difference of overall survival rate. Univariate analysis with Kaplan-Meier estimates revealed the specimens with CD73 positive staining were more likely to have an unfavorable survival (p 5 0.0027, Fig.  6d ). Consistent with this result, CD73 positive expression was found to be an independent prognostic factor in multivariate analysis with Cox hazard regression model (p 5 0.018, Supporting Information, Table 1 ). Taking advantage of the cancer genome atlas (TCGA) HNSC dataset, we performed survival analysis and gene set enrichment analysis (GSEA) enrichment between two groups based on NT5E mRNA expression level (Supporting Information, Fig. 5 and Table 2 ; NT5E top 25% vs. bottom 25%). Survival analysis showed NT5E hi group had significantly poorer prognosis than NT5E lo group (p 5 1.2 3 10
23
, Fig. 6e ). And the cutoff we selected in Kaplan-Meier survival plots (NT5E top 25% vs bottom 25%) was based on the best separation of survival curves of the high/low expression groups. Overall Survival of HNSCC patients, dichotomized according to the mean and median of NT5E mRNA level, still separated, with significance values of 0.0099 and 0.0043, respectively ( Supporting Information, Fig.  6 ). GSEA revealed that processes which negatively regulated immune effector were more active in NT5E hi group (q value 5 0.05, NES 5 1.55, Fig. 6f) . Thus, the CD73 expression has a clinical significance as a poor prognostic factor and these results raised the possibility that CD73 may have negative immunoregulatory role in HNSCC. Taken together, the results above prompted CD73 may be a potential target in human HNSCC and the efficiency of anti-CD73 in human HNSCC should be investigated in the future.
Discussion
Exhausted T cells express multiple inhibitory receptors, such as PD-1 and CTLA-4, and lose effector functions. 19 Using flow cytometry, we demonstrated the expression of PD-1 and CTLA-4 was significantly increased CD73
1 CD4 1 and CD73
1
CD8
1 T cells in the tumor-bearing mice, which indicated these CD73 1 population cell may represent an immunosuppressive status of HNSCC. In agreement with our observations, a previous research reported that CD4
1
CD73
1 population downregulated T-cell activation. 32 As the Tumor Immunology and Microenvironment Figure 5 . Anti-CD73 mAb treatment enriches "exhausted" phenotype in CD4 
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upstream component, CD73 works with A2AR to exert immunosuppressive function. A2AR activation suppress IFNg production but not T cell proliferation and this effect would last even after the removal of A2AR agonist. 33 In consistent with that report, our results show CD73 blockade increase IFN-g and decrease CTLA-4 as well as PD-1 expression in CD4
1 and CD8 1 T cells, which indicated that the T cell effector function was reinvigorated. Although the expression of CD73 is highly expressed on Tregs, Tregs is only a small part of CD4 1 T cells. Thus, the increased frequency of 1 and CD8 1 T cells and that CD73 inhibition lead to some degree of decrease of CTLA4 and PD-1. Therefore, we propose that high CD73 expression is a marker of exhausted T cells. Similarity, CD39 was defined as a marker of CD8 1 T cell exhaustion in a recent research. 34 Nevertheless, the populations of CD4 1 and CD8 1 T cells remain unchanged. Interestingly, the remaining CD73 1 population express even higher levels of PD-1 and CTLA-4. This result, to some extent, supports that targeting CD73 enhances the therapeutic efficiency of PD-1 or CTLA-4 blockade. 20 Thus, we hypothesize that anti-CD73 mAb treatment will reverse a large part of "exhausted" CD4
1 and CD8 1 T cells to immune-competent, however, the remaining CD73 1 CD4
1 and CD73
1
CD8
1 T cells, especially the CD73 hi subset, gains more inhibitory markers and becomes even more dysfunctional. Thus, this subset of CD73 hi T cells may represent a resistance to anti-CD73 mAb treatment.
Ectopic overexpression of CD73 involved in tumor progression is frequently observed. 16, 35, 36 In this study, using immunohistochemistry, we identify that CD73 is upregulated in the tumor infiltrating immune cells of HNSCC samples compared with normal mucosa. Increased expression of CD73 on tumor cells has been observed, and is associated with poor prognosis in human HNSCC. 13 In our study, we found CD73 is also highly expressed on the tumor infiltrating immune cells in human HNSCC samples, and confers poor prognosis in our cohort. Tumor cells expressed CD73 could convert AMP to adenosine, which exerts potent immunosuppressive effect. 16 However, CD73 highly expressed on T cell may be identified as an exhausted marker. Although there have been multiple reports relating CD73 to anti-tumor immunity in other tumors, [37] [38] [39] [40] [41] only few of them are focused on HNSCC. 42 Harnessing TCGA transcriptome sequencing data and R package TCGAbiolinks, 28, 29 we find out that NT5E mRNA level is also associated with negative immune regulation in HNSCC patients. Among the enriched genes, TGFB1 and TGFB2 were key factors in immunosuppression and TGFB1 was shown to induce immunosuppressive microenvironment in tumors. 43, 44 NDFIP1 negatively regulates T cell activation partly by limiting IL-2 expression. 45 although MKP-5 (DUSP10) is required for na€ ıve CD4 1 T cell activation, it negatively regulates CD4 1 and CD8 1 T cells in adaptive immunity. 46 IL-10 is known as an immunosuppressive cytokine which is secreted by a range of cells, IL-10 suppress the activation and proliferation of antigen-specific CD4 T cells that are vital to antitumor immunity. 47 IL-33 induces long-term immunosuppression by expanding Tregs population. 48 The contribution of adenosine in the modulation of immune response depends on CD39 and CD73, which converting ATP into AMP and adenosine.
12 CD39 is found on both human and mouse Tregs, whereas the expression of CD73 on human and mouse Tregs is ambiguous. 49 Some study proved CD73 is dramatically expressed on murine Tregs, but low levels of CD73 are detectable in human Tregs. 49 In contrast to this result, most of the Tregs expressed CD73 in human HNSCC patients. 42 The ultimate goal of this study is to develop a potential therapeutic strategy for targeted CD73 in human HNSCC. And this study is based on the HNSCC mouse model. Therefore, it is necessary to evaluate the expression and function of CD73 on T cells in human HNSCC. Indeed, we demonstrated that CD73 was overexpressed in tumor infiltrating immune cells of human HNSCC. However, lack of experimental research using human T cells is limitation of this study. Thus, detailed exploration of CD73 function on human T cells modulating tumor immunity in the future may facilitate to understand the immunosuppressive mechanisms in human HNSCC. Currently, The MEDI9447 (monoclonal antibody specific for CD73) alone and in combination with MEDI4736 (anti-PD-L1 monoclonal antibody) in select advanced solid tumor is recruiting participants (NCT02503774). In summary, we elucidate that the expression of CD73 on T cells represents an "exhausted" phenotype in competent HSNCC mouse model. Furthermore, in vivo assay showed the blockade of CD73 restrains tumor progression and reverses a large part of "exhausted" CD4 1 and CD8 1 T cells to immune-competent. Moreover, we showed a potential resistant population remaining CD73 positive during the anti-CD73 treatment. The human tumor samples reveal that CD73 is overexpressed in tumor-infiltrating immune cells, and the positive expression of CD73 is correlated with the poor prognosis in human HNSCC. Taken together, these data suggest that CD73 has a negative immunoregulatory function and it may prove to be a potential target for immunotherapy in HNSCC.
